The role of specific pancreatic antibodies in the differential diagnosis of complete clinical and laboratory remission of type 1 diabetes mellitus and MODY in children

BACKGROUND: T1D is characterized by autoimmune destruction of pancreatic β-cells, which develops due to genetic and environmental risk factors. Shortly after initiating the treatment with insulin, 80% of children with T1D may require smaller doses of insulin and develop clinical and laboratory remission of the disease so called «honeymoon». The issue of whether there is a need of differential diagnosis between autoimmune DM and non-immune forms of DM raises in cases of preclinical diagnosis of T1D and laboratory remission for more than 6 months.

AIM: To study the clinical, immunological, genetic characteristics of T1D remission phase and MODY in children, to determine the diagnostic criteria for T1D and MODY in children.

MATERIALS AND METHODS: A single-centre, cross sectional noncontrolled comparative study of two independent cohorts. Data of 150 children examined in the Endocrinology Research Center (January 2016–June 2021). First cohort included patients with complete clinical and laboratory remission of T1D (n=36), second cohort included patients with MODY, confirmed by genetic study (n=114).

RESULTS: The median age of diabetes manifestation was significantly higher in patients with T1D — 11.25 years [8.33; 13.78] than in patients with MODY — 7.5 years [4.6; 12.2] (p=0.004). In patients with T1D remission the level of glycated hemoglobin was 6.0% [5.6; 6.4], in group with MODY — 6.5% [6.2; 6.7] (p<0.001). Patients with monogenic diabetes had impaired fasting glucose — 6.27 mmol/l [5.38; 6.72], while patients with remission phase had normoglycemia — 5.12 mmol/l [4.17; 5.87]. The oral glucose tolerance test was perform to all patients, two-hour glucose level did not significantly differ in two groups (p=0.08). A strong family history of diabetes in patients with MODY registered more often (93% vs. 66.7%). A positive autoantibody titer detected more often in patients with remission of T1D (77.8%) than in patients with MODY (11.4%). In addition, no more than 1 type of autoantibodies was detected in patients with MODY.

CONCLUSION: Antibodies ZnT8 and IA2 showed the greatest significance for the differential diagnosis of T1D and MODY in cases with long absents of insulin requirement in children with diabetes mellitus. Genetic test is recommended in seronegative cases. If only one type of AT is detected, specialist should decide on the need to do diagnostic genetic test based on a comprehensive analysis of the patient’s clinic characteristics, including family history, manifestation and blood glucose levels.

1. Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD Clinical practice consensus guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018;19(S27):7-19. doi: https://doi.org/10.1111/pedi.12773

2. Sosenko JM, Skyler JS, Herold KC, Palmer JP. The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1. Diabetes. 2012;61(6):1331-1337. doi: https://doi.org/10.2337/db11-1660

3. Insel RA, Dunne JL, Atkinson MA, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi: https://doi.org/10.2337/dc15-1419

4. Lombardo F, Valenzise M, Wasniewska M, et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab. 2002;15(4):246-251.

5. Abdul-Rasoul M, Habib H, Al-Khouly M. “The honeymoon phase” in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7(2):101-107. doi: https://doi.org/10.1111/j.1399-543X.2006.00155.x

6. Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 2008;57(11):2883-2888. doi: https://doi.org/10.2337/db07-1817

7. Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, Characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab. 2013;98(10):4055-4062. doi: https://doi.org/10.1210/jc.2013-1279

8. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504-2508. doi: https://doi.org/10.1007/s00125-010-1799-4

9. Gioeva OA, Kolodkina AA, Vasilyev EV, et al. Hereditary variant of diabetes mellitus caused by a defect of the NEUROD1 gene (MODY6): the fi rst description in Russia. Problems of Endocrinology. 2016;62(3):16-20. (In Russ.). doi: https://doi.org/10.14341/probl201662316-20

10. Kuraeva TL, Sechko EA, Zilberman LI, et al. Molecular genetic and clinical variants MODY2 and MODY3 in children in Russia. Problems of Endocrinology. 2015;61(5):14-25. (In Russ.). doi: https://doi.org/10.14341/probl201561514-25

11. Mozzillo E, Salzano G, Barbetti F, et al. Survey on etiological diagnosis of diabetes in 1244 Italian diabetic children and adolescents: Impact of access to genetic testing. Diabetes Res Clin Pract. 2015;107(3):e15-e18. doi: https://doi.org/10.1016/j.diabres.2015.01.003

12. Fendler W, Borowiec M, Baranowska-Jazwiecka A, et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia. 2012;55(10):2631-2635. doi: https://doi.org/10.1007/s00125-012-2621-2

13. Bravis V, Kaur A, Walkey HC, et al. Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open. 2018;8(4):e020904. doi: https://doi.org/10.1136/bmjopen-2017-020904

14. Nagl K, Hermann JM, Plamper M, et al. Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose-adjusted HbA1c in 3657 children and adolescents from Germany and Austria: Partial remission based on IDAA1c. Pediatr Diabetes. 2017;18(6):428-434. doi: https://doi.org/10.1111/pedi.12413

15. Hattersley AT, Greeley SAW, Polak M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2018;19:47-63. doi: https://doi.org/10.1111/pedi.12772

16. Carlsson A, Shepherd M, Ellard S, et al. Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: Lessons from a 5-year pediatric Swedish National Cohort Study. Diabetes Care. 2020;43(1):82-89. doi: https://doi.org/10.2337/dc19-0747

17. Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009;26(5):466-473. doi: https://doi.org/10.1111/j.1464-5491.2009.02720.x

18. Urbanová J, Rypáčková B, Procházková Z, et al. Positivity for islet cell autoantibodies in patients with monogenic diabetes is associated with later diabetes onset and higher HbA 1c level. Diabet Med. 2014;31(4):466-471. doi: https://doi.org/10.1111/dme.12314

19. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes: Pancreatic autoantibodies can discriminate MODY from Type 1 diabetes. Diabet Med. 2011;28(9):1028-1033. doi: https://doi.org/10.1111/j.1464-5491.2011.03287.x

20. Parkkola A, Härkönen T, Ryhänen SJ, et al. The finnish pediatric diabetes register. extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. Diabetes Care. 2013;36(2):348-354. doi: https://doi.org/10.2337/dc12-0445

21. Kara Ö, Esen İ, Tepe D. Factors influencing frequency and duration of remission in children and adolescents newly diagnosed with type 1 diabetes. Med Sci Monit. 2018;24:5996-6001. doi: https://doi.org/10.12659/MSM.908450

22. Bowden SA, Duck MM, Hoffman RP. Young children (<5 yr) and adolescents (>12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes. 2008;9(3pt1):197-201. doi: https://doi.org/10.1111/j.1399-5448.2008.00376.x

23. Ovsyannikova АК, Shakhtshneider EV, Ivanoshchuk DE, et al. GCK-MODY diabetes course in persons over 18 years of age: prospective observation. Diabetes Mellitus. 2021;24(2):133-140. (In Russ.). doi: https://doi.org/10.14341/DM1231924

24. Aarthy R, Aston-Mourney K, Mikocka-Walus A, et al. Clinical features, complications and treatment of rarer forms of maturity-onset diabetes of the young (MODY) — A review. J Diabetes Complications. 2021;35(1):107640. doi: https://doi.org/10.1016/j.jdiacomp.2020.107640

25. Bonfanti R, Bognetti E, Meschi F, et al. Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty. Acta Diabetol. 1998;35(2):91-95. doi: https://doi.org/10.1007/s005920050110

26. Muhammad BJ, Swift PGF, Raymond NT, Botha JL. Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child. 1999;80(4):367-369. doi: https://doi.org/10.1136/adc.80.4.367

27. Komulainen J, Kulmala P, Savola K, et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care. 1999;22(12):1950-1955. doi: https://doi.org/10.2337/diacare.22.12.1950

28. Hathout EH, Hartwick N, Fagoaga OR, et al. Clinical, Autoimmune, and HLA Characteristics of Children Diagnosed With Type 1 Diabetes Before 5 Years of Age. Pediatrics. 2003;111(4):860-863. doi: https://doi.org/10.1542/peds.111.4.860

29. Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care. 2015;38(7):1383-1392. doi: https://doi.org/10.2337/dc14-2769

30. Sechko EA, Kuraeva TL, Zilberman LI, et al. Non-immune diabetes mellitus in children due to heterozygous mutations in the glucokinase gene (GCK-MODY): data of 144 patients. Diabetes mellitus. 2022;25(2):145-154. (In Russ.). doi: https://doi.org/10.14341/DM12819

31. Harries LW, Ellard S, Stride A, et al. Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum Mol Genet. 2006;15(14):2216-2224. doi: https://doi.org/10.1093/hmg/ddl147

32. Madariaga L, García-Castaño A, Ariceta G, et al. Variable phenotype in HNF1B mutations: extrarenal manifestations distinguish affected individuals from the population with congenital anomalies of the kidney and urinary tract. Clin Kidney J. 2019;12(3):373-379. doi: https://doi.org/10.1093/ckj/sfy102

33. Romanenkova EM, Eremina IA, Titovich EV, et al. C-peptide levels and the prevalence of islets autoantibodies in children with type 1 diabetes mellitus with different duration of the disease. Diabetes mellitus. 2022;25(2):155-165. (In Russ.). doi: https://doi.org/10.14341/DM12843